BACKGROUND: Recurrent atypical and malignant meningiomas have poor outcomes with surgical therapy alone. Neither adjuvant chemotherapy nor postoperative radiation therapy remedies this problem. OBJECTIVE: To evaluate our experience with the treatment of 15 patients treated with I-125 or Cs-131 brachytherapy radiation seeds as an adjuvant in these difficult cases. METHODS: Patients with high-grade recurrent meningioma who underwent resection and intraoperative placement of brachytherapy seeds at our institution from 2002 to 2014 were identified and studied by retrospective chart review. RESULTS: Fifteen patients with median age of 68.8 yr were treated with I-125 (n = 13) or Cs-131 (n = 2) brachytherapy seeds for cases of recurrent, grade II (n = 8), or grade III (n = 7) meningioma at our institution from 2002 to 2014. These lesions originated from a variety of locations including, convexity (3), falcine (3), frontal (2), occipital (1), parietal (2), 2 sphenoid wing (2), and temporal (2), based recurrent meningiomas. Patients had a median of 2 prior open surgical interventions and received local radiation therapy with a median dose of 55 Gy prior to brachytherapy. Survival at 2.5 yr was 56% for grade II and 17% for grade III lesions. Survival was significantly associated with patient age but not tumoral pathology. Forty percent of patients required reoperations for wound complications following brachytherapy. CONCLUSION: Brachytherapy with implantation of permanent radiation seeds provides a viable alternative treatment for recurrent meningioma while carrying a significant clinical risk of wound infection and need for reoperation. Published by Oxford University Press on behalf of Congress of Neurological Surgeons 2019.
BACKGROUND: Recurrent atypical and malignant meningiomas have poor outcomes with surgical therapy alone. Neither adjuvant chemotherapy nor postoperative radiation therapy remedies this problem. OBJECTIVE: To evaluate our experience with the treatment of 15 patients treated with I-125 or Cs-131 brachytherapy radiation seeds as an adjuvant in these difficult cases. METHODS:Patients with high-grade recurrent meningioma who underwent resection and intraoperative placement of brachytherapy seeds at our institution from 2002 to 2014 were identified and studied by retrospective chart review. RESULTS: Fifteen patients with median age of 68.8 yr were treated with I-125 (n = 13) or Cs-131 (n = 2) brachytherapy seeds for cases of recurrent, grade II (n = 8), or grade III (n = 7) meningioma at our institution from 2002 to 2014. These lesions originated from a variety of locations including, convexity (3), falcine (3), frontal (2), occipital (1), parietal (2), 2 sphenoid wing (2), and temporal (2), based recurrent meningiomas. Patients had a median of 2 prior open surgical interventions and received local radiation therapy with a median dose of 55 Gy prior to brachytherapy. Survival at 2.5 yr was 56% for grade II and 17% for grade III lesions. Survival was significantly associated with patient age but not tumoral pathology. Forty percent of patients required reoperations for wound complications following brachytherapy. CONCLUSION: Brachytherapy with implantation of permanent radiation seeds provides a viable alternative treatment for recurrent meningioma while carrying a significant clinical risk of wound infection and need for reoperation. Published by Oxford University Press on behalf of Congress of Neurological Surgeons 2019.
Authors: Wolfgang Wick; Thierry Gorlia; Martin Bendszus; Martin Taphoorn; Felix Sahm; Inga Harting; Alba A Brandes; Walter Taal; Julien Domont; Ahmed Idbaih; Mario Campone; Paul M Clement; Roger Stupp; Michel Fabbro; Emilie Le Rhun; Francois Dubois; Michael Weller; Andreas von Deimling; Vassilis Golfinopoulos; Jacoline C Bromberg; Michael Platten; Martin Klein; Martin J van den Bent Journal: N Engl J Med Date: 2017-11-16 Impact factor: 91.245
Authors: Ayal A Aizer; Wenya Linda Bi; Manjinder S Kandola; Eudocia Q Lee; Lakshmi Nayak; Mikael L Rinne; Andrew D Norden; Rameen Beroukhim; David A Reardon; Patrick Y Wen; Ossama Al-Mefty; Nils D Arvold; Ian F Dunn; Brian M Alexander Journal: Cancer Date: 2015-08-26 Impact factor: 6.860
Authors: Thomas J Kaley; Patrick Wen; David Schiff; Keith Ligon; Sam Haidar; Sasan Karimi; Andrew B Lassman; Craig P Nolan; Lisa M DeAngelis; Igor Gavrilovic; Andrew Norden; Jan Drappatz; Eudocia Quant Lee; Benjamin Purow; Scott R Plotkin; Tracy Batchelor; Lauren E Abrey; Antonio Omuro Journal: Neuro Oncol Date: 2014-08-06 Impact factor: 12.300
Authors: Stephen T Magill; Darryl Lau; David R Raleigh; Penny K Sneed; Shannon E Fogh; Michael W McDermott Journal: Neurosurgery Date: 2017-03-01 Impact factor: 4.654
Authors: Gurvinder Kaur; Eli T Sayegh; Andrew Larson; Orin Bloch; Michelle Madden; Matthew Z Sun; Igor J Barani; C David James; Andrew T Parsa Journal: Neuro Oncol Date: 2014-04-02 Impact factor: 12.300
Authors: Michael A Mooney; Wenya Linda Bi; Jonathan M Cantalino; Kyle C Wu; Thomas C Harris; Lucas L Possatti; Parikshit Juvekar; Liangge Hsu; Ian F Dunn; Ossama Al-Mefty; Phillip M Devlin Journal: J Neurooncol Date: 2019-11-19 Impact factor: 4.130